Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.50
- Piotroski Score 1.00
- Grade Buy
- Symbol (ALEC)
- Company Alector, Inc.
- Price $4.80
- Changes Percentage (5.49%)
- Change $0.25
- Day Low $4.52
- Day High $4.81
- Year High $8.90
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.39
- Trailing P/E Ratio -3.14
- Forward P/E Ratio -3.14
- P/E Growth -3.14
- Net Income $-130,391,000
Income Statement
Quarterly
Annual
Latest News of ALEC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Movie armorer on Alec Baldwin's film 'Rust' pleads guilty to gun charge in separate case
Movie armorer Hannah Gutierrez-Reed pleaded guilty to carrying a gun into a bar and agreed to 18 months of supervised probation in exchange for a reduced sentence. She also faces a prison term for inv...
By AP NEWS | 4 days ago -
Alec Bohm returning to Phillies' lineup for NLDS Game 3 after benching
Alec Bohm, struggling third baseman for the Phillies, will return to the starting lineup in Game 3 against the Mets. Despite recent poor performance, the team shows confidence in his abilities for the...
By CBS News | 4 days ago -
Slumping 3B Alec Bohm returning to Phillies' lineup for NLDS Game 3. Senga a Game 5 option for Mets
Alec Bohm will return to the Phillies' lineup for Game 3 against the Mets after a benching in Game 2. Bohm, an All-Star, has struggled recently but will start against Mets left-hander Sean Manaea....
By AP NEWS | 4 days ago
